Precision theranostics for better outcomes

We are pioneering theranostics that transform how bacterial infections are diagnosed and treated. With a focus on precision, our goal is to provide healthcare professionals with the tools to combat infections like Staphylococcus aureus (SA) at the source.

🌍 Improving infection outcomes through science-driven innovation

Sabiad team members Prof. Dr. Paul Jutte, Prof. Dr. Jan Maarten van Dijl, and Saskia van den Dool in an office setting, representing leadership in theranostics for bacterial infections.
📅 Founded in 2022
👤 Led led by Ton van den Hoven
📍 Headquartered in Netherlands
🔬 20+ years in infection diagnostics and therapy
Born from research, driven by impact

Our Story

Sabiad was founded in 2022 as a spin-off from the University Medical Center Groningen (UMCG), building on over 20 years of research led by Prof. Jan Maarten van Dijl.

Our journey began with a simple yet powerful concept: to combine diagnostics and therapy into one seamless process to more effectively treat bacterial infections. Today, this idea has grown into a company committed to revolutionizing infection management.

Fighting Infections with precision and passion

Our Vision

“To become the global leader in non-oncology theranostics, transforming the way bacterial infections are diagnosed and treated, setting new standards in precision healthcare, and reducing the global burden of antimicrobial resistance.” 

We envision a future where healthcare professionals have the real-time insights and tools they need to fight bacterial infections effectively, minimizing the need for antibiotics and preventing complications like biofilm formation. Our work is driven by the belief that infection management can be both accurate and patient-specific.

Our theranostic technology integrates diagnostics and therapeutics, representing a breakthrough in personalized care, especially for infections linked to surgical procedures such as Total Joint Replacements (TJR) and Fracture-Related Infections (FRI).

Why StaphMark?

StaphMark vial as staphylococcus aureus infection solution

Surgical infections, particularly those caused by Staphylococcus aureus, are notoriously difficult to treat. Our patented StaphMark platform is designed to meet this challenge head-on. It uses the 1D9 antibody to pinpoint and visualize infections and deliver targeted treatment in real time, whether in the operating room or via point-of-care diagnostics.

We are pushing the boundaries of bacterial theranostics to minimize the overuse of antibiotics and improve recovery for patients worldwide.

The key to precision detection

Our Values

& Mission! We are on a mission to deliver innovative theranostic solutions that improve the diagnosis and treatment of bacterial infections, reduce healthcare costs, and combat antimicrobial resistance. We believe in personalized, data-driven care that adapts to each patient's needs.

Precision icon

Precision

Everything we do is driven by accuracy, from diagnostics to treatment, ensuring we get it right the first time.

Pastel target icon

Collaboration

Our success depends on working closely with healthcare providers, researchers, and partners to bring our solutions to those who need them.

Integrity icon

Integrity

We are committed to maintaining the highest standards of ethics and transparency, ensuring that our solutions are safe and effective.

Patient centered icon

Patient-centered

The well-being of patients is our top priority, with every solution aimed at improving their quality of life and care.

Light bulb innovation icon

Innovation

We push boundaries to create breakthrough technologies that make bacterial infection management faster, more effective, and less dependent on antibiotics.

Ton van den Hoven

Ton van den Hoven

Co-Founder & Chief Executive Officer

Serial entrepreneur with a track record of founding and scaling multiple successful healthcare technology startups.

Saskia van den Dool

Saskia van den Dool

Co-Founder & Chief Operating Officer

Strategic business leader with a background in developing and executing growth strategies that have led to significant revenue increases.

Jan Maarten van Dijl

Prof. Dr. Jan Maarten van Dijl

Co-Founder & Chief Scientific Officer

Renowned scientist with a track record of groundbreaking research in Medical Microbiology and over a decade of experience in advancing clinical diagnostics.

Ard Boerema

Ard Boerema

CFO

Senior Finance executive with extensive experience in controlling, reporting, planning and business improvements.

Jonathan Shaheen

Jonathan Shaheen, Ph.D.

Product Development

Pharmacist specializing in product development with experience in creating innovative fluorescent healthcare solutions.

Yge de Haan

Yge de Haan

Senior Project Manager

Senior operations expert with a history of project-related operations driving successful compliance.

Dr. Paul Jutte

Prof. Dr. Paul Jutte

Clinical Advisor Orthopedics

Orthopedic Surgeon and chair of the orthopedics group at the UMCG.

Dr. Wouter Nagengast

Prof. Dr. Wouter Nagengast

Advisor Product Development

Gastroenterologist and Pharmacist and chair of the OMIG group at the UMCG.

Dr. Philip Elsinga

Prof. Dr. Philip H Elsinga

Advisor Radio Chemistry

Serial entrepreneur with a track record of founding and scaling multiple successful healthcare technology startups.

Dominika Gazdik

Dominika Gazdik

Marketer, Designer & Web Developer

Specializes in marketing, design, and web development.

Devlina Ghosh

Devlina Ghosh

Clinical Research Coordinator

Experienced Clinical Research Coordinator.

Scientific Partners.

Our Partners.